Chugai’s HEMLIBRA® Receives Priority Review Status from U.S. FDA for Hemophilia A Without Inhibitors
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drugs Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for HEMLIBRA® [US generic name: emicizumab-kxwh] for adults and children with hemophilia A without factor VIII inhibitors. The FDA is expected to make a decision on approval by 4 October, 2018. In the US, Genentech, Inc., a member of Roche Group is the BLA holder and is engaged in the development and distribution of HEMLIBRA, which was approved and launched for hemophilia A with inhibitors in November 2017.
“We are very proud that HEMLIBRA has been granted a second Priority Review for hemophilia A without inhibitors following the previous designation for hemophilia A with inhibitors, which underscores the innovation of this drug,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “In treatment of hemophilia A without inhibitors, there still remain unmet medical needs in the management of bleeding. Given this Priority Review status, we hope to be able to contribute to people with hemophilia A and their caregivers as soon as possible by providing HEMLIBRA as a new treatment option that can be administered subcutaneously with good bleeding control and eased treatment burden.”
The sBLA filing and Priority Review are based on the results of HAVEN 3 study (NCT02847637), which has been conducted with adults and adolescents with hemophilia A without factor VIII inhibitors under a collaboration between Chugai, Roche and Genentech. In EU, Roche has already filed the results to the European Medicines Agency for a supplemental indication of hemophilia A without inhibitors.
Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in safety or effectiveness of the treatment, prevention or diagnosis of a serious disease. In Japan, HEMLIBRA received regulatory approval in March 2018 for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital factor VIII deficiency (hemophilia A) with factor VIII inhibitors and, in April 2018, was filed to the Ministry of Health, Labour and Welfare for a supplemental indication of hemophilia A without inhibitors.
Trademarks used or mentioned in this release are protected by law.
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totaled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Enevate Secures Funding from LG Chem to Accelerate Fast Charge Li-Ion Battery Technology Development for Electric Vehicles23.10.2018 13:00 | Tiedote
Enevate Corporation, an advanced lithium-ion (Li-ion) battery technology company, announced that LG Chem, a leading high volume battery manufacturer in South Korea, has participated in Enevate’s recent funding. This investment is a nod to the viability of Enevate’s technology which could enable Electric Vehicles (EVs) to charge in the same time as gas cars without compromise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005147/en/ Enevate’s HD-Energy® Technology for EVs allows Li-ion batteries to be charged to 75 percent capacity in five minutes, while also providing higher energy densities than available for today’s current long-range EVs. They can also safely charge and discharge down to -40°C and capture more energy during regenerative braking, extending their range in cold climates. “The strategic investment from LG Chem indicates the significance of our technology because it could directly address consumer conce
STEMCELL Submits Drug Master File for mTeSR™1, the Most Widely Published Cell Culture Medium for Human Pluripotent Stem Cells23.10.2018 13:00 | Tiedote
STEMCELL Technologies announced it has filed a Type II Drug Master File (DMF) to the Food and Drug Administration (FDA) for the Cellular Therapy Ancillary Material mTeSR™1 and has been issued DMF# 18339. mTeSR™1 is an Ancillary Material used in basic and translational research to maintain and expand human pluripotent stem cells (hPSCs) in the undifferentiated state. Used in over 1500 peer-reviewed publications, mTeSR™1 is the most widely published feeder-free cell culture medium, with established protocols for applications ranging from cell line derivation to terminal differentiation. With pre-screened raw materials that ensure batch-to-batch consistency, mTeSR™1 provides robust cultures with homogeneous, undifferentiated phenotypes. “Advancing our cGMP (Current Good Manufacturing Practices) Ancillary Material suite of products is a top priority for STEMCELL. This further demonstrates to our customers that we are a trusted partner for their bench to bedside translational journey,” says
Malta and Austria Are Home to the World’s Best Investment Migration Programs23.10.2018 12:00 | Tiedote
The Malta Individual Investor Program is the world’s top citizenship-by-investment program and the Austria Private Residence Program is the world’s top residence-by-investment program, according to the Global Residence and Citizenship Programs 2018–2019 report, released today by global residence and citizenship advisory firm Henley & Partners. Dr. Christian H. Kälin, an international immigration and citizenship law expert and Group Chairman of Henley & Partners, says the annual report provides a systematic analysis and comprehensive benchmarking of the world’s most important programs. “It’s an invaluable tool for anyone interested in alternative residence or citizenship as well as for the professionals like private bankers and lawyers who advise them. It also provides governments with a detailed picture of the broader investment migration industry landscape and where they fit it.” Malta is followed in the citizenship program ranking by Cyprus in 2nd place, Austria in 3rd place, and Ant
Temenos Ramps up AI Efforts to Power its Digital Banking Platform23.10.2018 11:30 | Tiedote
Temenos (SIX: TEMN), the banking software company, today announced during the Machine Learning Panel at Sibos that it is increasing the development of Artificial Intelligence capabilities throughout its digital banking platform. The Temenos AI initiative will enable banks to offer personalized services to customers, augment users’ decisions with data-driven machine intelligence, and maximise straight-through-processing (STP) rates for financial transactions at reduced cost with limited or no human intervention. As part of this global initiative, Temenos has just launched a Centre of Excellence for Artificial Intelligence as its innovation engine. The Temenos AI Centre of Excellence will foster a collaborative ecosystem with Temenos’ banking clients and partners to help identify and validate use cases where AI could have an immediate impact on customer experience, as well as operational excellence, and hence improve the bottom line. Temenos’ pioneering initiative will involve injecting
ECAC EDS CB C3 Approval for Smiths Detection Technology23.10.2018 11:00 | Tiedote
Smiths Detection has gained ECAC EDS CB C3 approval for the innovative HI-SCAN 6040 CTiX checkpoint scanner. This eliminates the need to remove electronic devices and liquids from hand luggage (subject to local authority guidelines) to make the process more passenger friendly. The HI-SCAN 6040 CTiX delivers the highest levels of security demanded by the new regulations, whilst optimizing checkpoint performance through improved productivity, a better passenger experience and lower operational costs. Removing the need to take out electronic devices and liquids from hand luggage means handling fewer trays which can significantly increase checkpoint throughput and the impressive 0.2m/s belt speed and low false alarm rate also speed up the process. “As the only technology meeting EDS CB C3 (and potentially future C4) standards, Computed Tomography (CT) is undoubtedly the way forward for checkpoint security,” commented Matt Clark, VP Technology & Product Development, Smiths Detection. “With
VIB 9–month profit before tax rises 176% YoY to VND 1,720 billion, Retail revenue increases 92% YoY23.10.2018 10:48 | Tiedote
Vietnam International Bank (UPCoM: VIB) announced its financial statements of the first 9 months 2018 with positive results. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005507/en/ A clerk at VIB (Photo: Business Wire) Profit before tax grows 176% VIB reported profit before tax of VND 1,720 billion, up 176% year-on-year (YoY), equal to 86% of its full year target. The revenue increased by 48% YoY, in which interest income and non-interest income up 50% and 37% respectively; the latter accounted for 16% of total revenue and continued upward trend. The cost-to-income ratio (CIR) significantly dropped from 57% in 2017 to 48%. Provision expense in 9 months was lower than YoY in the context that VIB no longer has bad debts in VAMC. The return on equity ratio (ROE) reached 19.4%. The total asset of the bank reached over VND 132,500 billion, up 8% year-to-date; lending and deposits reached VND 95,200 billion and VND 89,200
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme